$MOH
MOLINA HEALTHCARE, INC.

2022 Q3 Form 10-Q Financial Statement

#000117992922000112 Filed on July 28, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $7.927B $8.054B $7.770B
YoY Change 12.6% 18.44% 19.14%
Cost Of Revenue $6.748B $6.872B $6.563B
YoY Change 11.56% 18.1% 19.89%
Gross Profit $1.179B $1.182B $1.207B
YoY Change 18.97% 20.49% 15.17%
Gross Profit Margin 14.87% 14.68% 15.53%
Selling, General & Admin $783.0M $766.0M $779.0M
YoY Change 6.39% 14.5% 18.03%
% of Gross Profit 66.41% 64.81% 64.54%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $45.00M $44.00M $40.00M
YoY Change 40.63% 41.94% 21.21%
% of Gross Profit 3.82% 3.72% 3.31%
Operating Expenses $828.0M $810.0M $819.0M
YoY Change 7.81% 15.71% 18.18%
Operating Profit $335.0M $361.0M $372.0M
YoY Change 51.58% 32.23% 11.04%
Interest Expense $28.00M $27.00M $28.00M
YoY Change -6.67% -10.0% -6.67%
% of Operating Profit 8.36% 7.48% 7.53%
Other Income/Expense, Net -$28.00M -$27.00M -$28.00M
YoY Change -6.67% -10.0% -6.67%
Pretax Income $307.0M $334.0M $344.0M
YoY Change 60.73% 37.45% 12.79%
Income Tax $77.00M $86.00M $86.00M
% Of Pretax Income 25.08% 25.75% 25.0%
Net Earnings $230.0M $248.0M $258.0M
YoY Change 60.84% 34.05% 13.16%
Net Earnings / Revenue 2.9% 3.08% 3.32%
Basic Earnings Per Share $4.00 $4.29 $4.45
Diluted Earnings Per Share $3.95 $4.25 $4.39
COMMON SHARES
Basic Shares Outstanding 58.10M shares 57.80M shares 58.00M shares
Diluted Shares Outstanding 58.30M shares 58.40M shares 58.70M shares

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.881B $7.879B $7.792B
YoY Change 8.6% 15.04% 22.34%
Cash & Equivalents $4.242B $4.312B $4.804B
Short-Term Investments $3.639B $3.567B $2.988B
Other Short-Term Assets $391.0M $213.0M $198.0M
YoY Change 98.48% 26.79% 21.47%
Inventory
Prepaid Expenses
Receivables $2.220B $2.240B $2.156B
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $10.49B $10.33B $10.15B
YoY Change 12.02% 16.43% 22.12%
LONG-TERM ASSETS
Property, Plant & Equipment $412.0M $401.0M $393.0M
YoY Change 7.01% 4.7% 3.97%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $186.0M $193.0M $181.0M
YoY Change 45.31% 44.03% 32.12%
Total Long-Term Assets $2.301B $2.240B $2.214B
YoY Change 38.03% 35.27% 34.84%
TOTAL ASSETS
Total Short-Term Assets $10.49B $10.33B $10.15B
Total Long-Term Assets $2.301B $2.240B $2.214B
Total Assets $12.79B $12.57B $12.36B
YoY Change 15.95% 19.39% 24.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $818.0M $715.0M $809.0M
YoY Change 2.63% 9.83% 16.4%
Accrued Expenses
YoY Change
Deferred Revenue $663.0M $13.00M $18.00M
YoY Change 66200.0% -69.05% -74.65%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.242B $7.225B $7.041B
YoY Change 19.31% 26.6% 32.28%
LONG-TERM LIABILITIES
Long-Term Debt $2.175B $2.175B $2.174B
YoY Change 2.11% 2.16% 2.16%
Other Long-Term Liabilities $118.0M $126.0M $134.0M
YoY Change 24.21% 24.75% 19.64%
Total Long-Term Liabilities $2.293B $2.301B $2.308B
YoY Change 3.06% 3.18% 3.04%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.242B $7.225B $7.041B
Total Long-Term Liabilities $2.293B $2.301B $2.308B
Total Liabilities $9.752B $9.742B $9.566B
YoY Change 14.53% 19.39% 22.86%
SHAREHOLDERS EQUITY
Retained Earnings $2.937B $2.707B $2.657B
YoY Change 27.92% 25.73% 35.01%
Common Stock $289.0M $251.0M $218.0M
YoY Change 40.98% 31.41% 28.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.041B $2.830B $2.794B
YoY Change
Total Liabilities & Shareholders Equity $12.79B $12.57B $12.36B
YoY Change 15.95% 19.39% 24.22%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income $230.0M $248.0M $258.0M
YoY Change 60.84% 34.05% 13.16%
Depreciation, Depletion And Amortization $45.00M $44.00M $40.00M
YoY Change 40.63% 41.94% 21.21%
Cash From Operating Activities $254.0M $368.0M $363.0M
YoY Change -44.9% -25.35% -36.09%
INVESTING ACTIVITIES
Capital Expenditures -$31.00M -$27.00M $23.00M
YoY Change 14.81% 107.69% 43.75%
Acquisitions
YoY Change
Other Investing Activities -$316.0M -$638.0M $13.00M
YoY Change -52.91% 107.14% -244.44%
Cash From Investing Activities -$347.0M -$665.0M $74.00M
YoY Change -50.29% 107.17% -185.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.00M -191.0M -$77.00M
YoY Change -350.0% -2828.57% -62.8%
NET CHANGE
Cash From Operating Activities 254.0M 368.0M $363.0M
Cash From Investing Activities -347.0M -665.0M $74.00M
Cash From Financing Activities 10.00M -191.0M -$77.00M
Net Change In Cash -83.00M -488.0M $360.0M
YoY Change -65.56% -372.63% 31.39%
FREE CASH FLOW
Cash From Operating Activities $254.0M $368.0M $363.0M
Capital Expenditures -$31.00M -$27.00M $23.00M
Free Cash Flow $285.0M $395.0M $340.0M
YoY Change -41.6% -21.94% -38.41%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001179929
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-31719
dei Entity Registrant Name
EntityRegistrantName
MOLINA HEALTHCARE, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
13-4204626
dei Entity Address Address Line1
EntityAddressAddressLine1
200 Oceangate
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
dei Entity Address City Or Town
EntityAddressCityOrTown
Long Beach,
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
90802
dei City Area Code
CityAreaCode
562
dei Local Phone Number
LocalPhoneNumber
435-3666
dei Security12b Title
Security12bTitle
Common Stock, $0.001 Par Value
dei Trading Symbol
TradingSymbol
MOH
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
58100000 shares
CY2022Q2 us-gaap Premiums Earned Net
PremiumsEarnedNet
7799000000 usd
CY2021Q2 us-gaap Premiums Earned Net
PremiumsEarnedNet
6583000000 usd
us-gaap Premiums Earned Net
PremiumsEarnedNet
15330000000 usd
us-gaap Premiums Earned Net
PremiumsEarnedNet
12889000000 usd
CY2022Q2 moh Health Care Organization Premium Tax Revenue
HealthCareOrganizationPremiumTaxRevenue
215000000 usd
CY2021Q2 moh Health Care Organization Premium Tax Revenue
HealthCareOrganizationPremiumTaxRevenue
185000000 usd
moh Health Care Organization Premium Tax Revenue
HealthCareOrganizationPremiumTaxRevenue
423000000 usd
moh Health Care Organization Premium Tax Revenue
HealthCareOrganizationPremiumTaxRevenue
372000000 usd
CY2022Q2 us-gaap Net Investment Income
NetInvestmentIncome
22000000 usd
CY2021Q2 us-gaap Net Investment Income
NetInvestmentIncome
10000000 usd
us-gaap Net Investment Income
NetInvestmentIncome
33000000 usd
us-gaap Net Investment Income
NetInvestmentIncome
19000000 usd
CY2022Q2 us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
18000000 usd
CY2021Q2 us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
22000000 usd
us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
38000000 usd
us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
42000000 usd
CY2022Q2 us-gaap Revenues
Revenues
8054000000 usd
CY2021Q2 us-gaap Revenues
Revenues
6800000000 usd
us-gaap Revenues
Revenues
15824000000 usd
us-gaap Revenues
Revenues
13322000000 usd
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6872000000 usd
CY2021Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5819000000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
13435000000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
11293000000 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
551000000 usd
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
484000000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1122000000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
957000000 usd
CY2022Q2 moh Premium Tax Expenses
PremiumTaxExpenses
215000000 usd
CY2021Q2 moh Premium Tax Expenses
PremiumTaxExpenses
185000000 usd
moh Premium Tax Expenses
PremiumTaxExpenses
423000000 usd
moh Premium Tax Expenses
PremiumTaxExpenses
372000000 usd
CY2022Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
44000000 usd
CY2021Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
31000000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
84000000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
64000000 usd
CY2022Q2 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
11000000 usd
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
7.05
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
135000000 usd
CY2021Q2 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
8000000 usd
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
27000000 usd
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
28000000 usd
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
7693000000 usd
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
6527000000 usd
us-gaap Costs And Expenses
CostsAndExpenses
15091000000 usd
us-gaap Costs And Expenses
CostsAndExpenses
12714000000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
361000000 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
273000000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
733000000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
608000000 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
27000000 usd
CY2021Q2 us-gaap Interest Expense
InterestExpense
30000000 usd
us-gaap Interest Expense
InterestExpense
55000000 usd
us-gaap Interest Expense
InterestExpense
60000000 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-27000000 usd
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-30000000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-55000000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-60000000 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
334000000 usd
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
243000000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
678000000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
548000000 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
86000000 usd
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
58000000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
172000000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
248000000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
185000000 usd
us-gaap Net Income Loss
NetIncomeLoss
506000000 usd
us-gaap Net Income Loss
NetIncomeLoss
413000000 usd
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.29
us-gaap Net Income Loss
NetIncomeLoss
506000000 usd
us-gaap Net Income Loss
NetIncomeLoss
413000000 usd
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.20
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
8.74
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
7.14
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.25
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.16
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
8.63
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
248000000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
185000000 usd
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-62000000 usd
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
1000000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-162000000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-14000000 usd
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-15000000 usd
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
1000000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-39000000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-3000000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-47000000 usd
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-123000000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-11000000 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
201000000 usd
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
185000000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
383000000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
402000000 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4312000000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4438000000 usd
CY2022Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
3567000000 usd
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
3202000000 usd
CY2022Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
2240000000 usd
CY2021Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
2177000000 usd
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
213000000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
247000000 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
10332000000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
10064000000 usd
CY2022Q2 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
401000000 usd
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
396000000 usd
CY2022Q2 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
1286000000 usd
CY2021Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
1252000000 usd
CY2022Q2 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
219000000 usd
CY2021Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
212000000 usd
CY2022Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
141000000 usd
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
106000000 usd
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
193000000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
179000000 usd
CY2022Q2 us-gaap Assets
Assets
12572000000 usd
CY2021Q4 us-gaap Assets
Assets
12209000000 usd
CY2022Q2 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
3775000000 usd
CY2021Q4 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
3363000000 usd
CY2022Q2 moh Medical Premium Liability Due To Agency
MedicalPremiumLiabilityDueToAgency
2722000000 usd
CY2021Q4 moh Medical Premium Liability Due To Agency
MedicalPremiumLiabilityDueToAgency
2472000000 usd
CY2022Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
715000000 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
842000000 usd
CY2022Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
13000000 usd
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
370000000 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
7225000000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7047000000 usd
CY2022Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2175000000 usd
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2173000000 usd
CY2022Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
216000000 usd
CY2021Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
219000000 usd
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
126000000 usd
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
140000000 usd
CY2022Q2 us-gaap Liabilities
Liabilities
9742000000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
9579000000 usd
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58000000 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58000000 shares
CY2022Q2 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
0 usd
CY2021Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
0 usd
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
251000000 usd
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
236000000 usd
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-128000000 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5000000 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
2707000000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
2399000000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
2830000000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
2630000000 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12572000000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12209000000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
2630000000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
258000000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-76000000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-18000000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
2794000000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
248000000 usd
CY2022Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
200000000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-47000000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
35000000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
2830000000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
2096000000 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
228000000 usd
CY2021Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
122000000 usd
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-11000000 usd
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-27000000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
2164000000 usd
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
43000000 usd
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
192000000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
185000000 usd
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
21000000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
2370000000 usd
us-gaap Net Income Loss
NetIncomeLoss
506000000 usd
us-gaap Net Income Loss
NetIncomeLoss
413000000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
84000000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
64000000 usd
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-3000000 usd
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-7000000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
57000000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
35000000 usd
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-6000000 usd
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
10000000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
64000000 usd
CY2021Q3 moh Health Plan Extension Option Period
HealthPlanExtensionOptionPeriod
P2Y
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6000000 usd
us-gaap Increase Decrease In Health Care Insurance Liabilities
IncreaseDecreaseInHealthCareInsuranceLiabilities
405000000 usd
us-gaap Increase Decrease In Health Care Insurance Liabilities
IncreaseDecreaseInHealthCareInsuranceLiabilities
272000000 usd
moh Increase Decrease In Medical Premium Liability Due To Agency
IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency
247000000 usd
moh Increase Decrease In Medical Premium Liability Due To Agency
IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency
792000000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-147000000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-15000000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-357000000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-333000000 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
46000000 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
14000000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
731000000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1061000000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
1413000000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
1006000000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
879000000 usd
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
20000000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
622000000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
50000000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
29000000 usd
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
7000000 usd
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-5000000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-591000000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-408000000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
200000000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
128000000 usd
moh Common Stock Withheld To Settle Employee Tax Obligations
CommonStockWithheldToSettleEmployeeTaxObligations
53000000 usd
moh Common Stock Withheld To Settle Employee Tax Obligations
CommonStockWithheldToSettleEmployeeTaxObligations
52000000 usd
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
20000000 usd
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
5000000 usd
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-268000000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-200000000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-128000000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
453000000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4506000000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4223000000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4378000000 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4676000000 usd
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
4 segment
CY2021Q3 moh Health Plan Contract Term
HealthPlanContractTerm
P4Y
us-gaap Use Of Estimates
UseOfEstimates
Use of EstimatesThe preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4312000000 usd
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4608000000 usd
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
66000000 usd
CY2021Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
68000000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4378000000 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4676000000 usd
CY2022Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
2240000000 usd
CY2021Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
2177000000 usd
CY2022Q2 moh Medical Premiums Liability Medical Care Costs Threshold
MedicalPremiumsLiabilityMedicalCareCostsThreshold
1018000000 usd
CY2021Q4 moh Medical Premiums Liability Medical Care Costs Threshold
MedicalPremiumsLiabilityMedicalCareCostsThreshold
1016000000 usd
CY2022Q2 moh Amounts Due To Government Agencies Medicaid Other
AmountsDueToGovernmentAgenciesMedicaidOther
402000000 usd
CY2021Q4 moh Amounts Due To Government Agencies Medicaid Other
AmountsDueToGovernmentAgenciesMedicaidOther
263000000 usd
CY2022Q2 moh Amounts Due To Government Agencies Risk Adjustment And Part D Risk Sharing
AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing
68000000 usd
CY2021Q4 moh Amounts Due To Government Agencies Risk Adjustment And Part D Risk Sharing
AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing
89000000 usd
CY2022Q2 moh Amounts Due To Government Agencies Medicare Medical Loss Ratio And Profit Sharing Threshold
AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold
115000000 usd
CY2021Q4 moh Amounts Due To Government Agencies Medicare Medical Loss Ratio And Profit Sharing Threshold
AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold
101000000 usd
CY2022Q2 moh Other Medicare Program
OtherMedicareProgram
22000000 usd
CY2021Q4 moh Other Medicare Program
OtherMedicareProgram
35000000 usd
CY2022Q2 moh Amounts Dueto Government Agencies Risk Adjustment
AmountsDuetoGovernmentAgenciesRiskAdjustment
1037000000 usd
CY2021Q4 moh Amounts Dueto Government Agencies Risk Adjustment
AmountsDuetoGovernmentAgenciesRiskAdjustment
902000000 usd
CY2022Q2 moh Amounts Due To Government Agencies Marketplace Medical Loss Ratio Threshold
AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold
7000000 usd
CY2021Q4 moh Amounts Due To Government Agencies Marketplace Medical Loss Ratio Threshold
AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold
18000000 usd
CY2022Q2 moh Amounts Dueto Government Agencies Other
AmountsDuetoGovernmentAgenciesOther
53000000 usd
CY2021Q4 moh Amounts Dueto Government Agencies Other
AmountsDuetoGovernmentAgenciesOther
48000000 usd
CY2022Q2 moh Medical Premium Liability Due To Agency
MedicalPremiumLiabilityDueToAgency
2722000000 usd
CY2021Q4 moh Medical Premium Liability Due To Agency
MedicalPremiumLiabilityDueToAgency
2472000000 usd
CY2022Q2 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Payable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable
1037000000 usd
CY2022Q2 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Receivable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable
61000000 usd
CY2022Q2 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Net Payable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable
-976000000 usd
CY2021Q4 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Payable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable
902000000 usd
CY2021Q4 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Receivable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable
7000000 usd
CY2021Q4 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Net Payable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable
895000000 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with final maturities of less than 15 years, or less than 15 years average life for structured securities. Restricted investments are invested principally in cash, cash equivalents, and U.S. Treasury securities. Concentration of credit risk with respect to accounts receivable is limited because our payors consist principally of the federal government, and governments of each state in which our health plan subsidiaries operate.</span></div>
moh Investments Maturity Period
InvestmentsMaturityPeriod
P15Y
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
248000000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
185000000 usd
us-gaap Net Income Loss
NetIncomeLoss
506000000 usd
us-gaap Net Income Loss
NetIncomeLoss
413000000 usd
CY2022Q1 moh Shares Outstanding Excluding Restricted Stock Awards
SharesOutstandingExcludingRestrictedStockAwards
58100000 shares
CY2021Q1 moh Shares Outstanding Excluding Restricted Stock Awards
SharesOutstandingExcludingRestrictedStockAwards
57700000 shares
CY2021Q4 moh Shares Outstanding Excluding Restricted Stock Awards
SharesOutstandingExcludingRestrictedStockAwards
57900000 shares
CY2020Q4 moh Shares Outstanding Excluding Restricted Stock Awards
SharesOutstandingExcludingRestrictedStockAwards
58000000.0 shares
CY2022Q2 moh Weighted Average Numberof Shares Share Based Compensation
WeightedAverageNumberofSharesShareBasedCompensation
0 shares
CY2021Q2 moh Weighted Average Numberof Shares Share Based Compensation
WeightedAverageNumberofSharesShareBasedCompensation
0 shares
moh Weighted Average Numberof Shares Share Based Compensation
WeightedAverageNumberofSharesShareBasedCompensation
200000 shares
moh Weighted Average Numberof Shares Share Based Compensation
WeightedAverageNumberofSharesShareBasedCompensation
200000 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
300000 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0 shares
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
200000 shares
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
500000 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57800000 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57700000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57900000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57700000 shares
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.29
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.20
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
8.74
CY2022Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
600000 shares
CY2021Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
700000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
700000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
800000 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58400000 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58400000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58600000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58500000 shares
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
7.14
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.25
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.16
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
8.63
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
7.05
us-gaap Gain Loss On Fair Value Hedges Recognized In Earnings
GainLossOnFairValueHedgesRecognizedInEarnings
-4000000 usd
us-gaap Gain Loss On Fair Value Hedges Recognized In Earnings
GainLossOnFairValueHedgesRecognizedInEarnings
-3000000 usd
CY2022Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
3567000000 usd
CY2022Q2 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
8000000 usd
CY2022Q2 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
8000000 usd
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
3202000000 usd
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
47000000 usd
CY2021Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
47000000 usd
us-gaap Gain Loss On Fair Value Hedges Recognized In Earnings
GainLossOnFairValueHedgesRecognizedInEarnings
-4000000 usd
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
20000000 usd
CY2022Q2 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
3735000000 usd
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000000 usd
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
170000000 usd
CY2022Q2 us-gaap Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
3567000000 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
3208000000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
12000000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
18000000 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
3202000000 usd
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
340000000 usd
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
338000000 usd
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
2276000000 usd
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
2175000000 usd
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost
377000000 usd
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
358000000 usd
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities After Ten Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost
742000000 usd
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities After Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
696000000 usd
CY2022Q2 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
3735000000 usd
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
3567000000 usd
CY2022Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
3009000000 usd
CY2022Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
166000000 usd
CY2022Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
1466 position
CY2022Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
86000000 usd
CY2022Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
4000000 usd
CY2022Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
45 position
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
1706000000 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
18000000 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
677 position
CY2022Q2 us-gaap Debt Securities Held To Maturity Excluding Accrued Interest Before Allowance For Credit Loss
DebtSecuritiesHeldToMaturityExcludingAccruedInterestBeforeAllowanceForCreditLoss
219000000 usd
CY2022Q2 us-gaap Held To Maturity Securities Debt Maturities Within One Year Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount
191000000 usd
CY2022Q2 us-gaap Held To Maturity Securities Debt Maturities After One Through Five Years Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount
28000000 usd
us-gaap Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense
ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the details of our medical claims and benefits payable as of the dates indicated:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Claims incurred but not paid (“IBNP”)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,719 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,486 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacy payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">229 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitation payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">733 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">576 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,775 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,363 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div>
CY2022Q2 moh Liabilityfor Unpaid Claimsand Claims Adjustment Expense Incurredbut Not Paid Ibnp Feeforservice Claims Amount
LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount
2719000000 usd
CY2021Q4 moh Liabilityfor Unpaid Claimsand Claims Adjustment Expense Incurredbut Not Paid Ibnp Feeforservice Claims Amount
LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount
2486000000 usd
CY2022Q2 moh Pharmacy Claims Payable
PharmacyClaimsPayable
229000000 usd
CY2021Q4 moh Pharmacy Claims Payable
PharmacyClaimsPayable
219000000 usd
CY2022Q2 moh Capitation Claims Payable
CapitationClaimsPayable
94000000 usd
CY2021Q4 moh Capitation Claims Payable
CapitationClaimsPayable
82000000 usd
CY2022Q2 moh Other Claims Payable
OtherClaimsPayable
733000000 usd
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
-193000000 usd
CY2021Q4 moh Other Claims Payable
OtherClaimsPayable
576000000 usd
CY2022Q2 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
3775000000 usd
CY2021Q4 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
3363000000 usd
CY2022Q2 moh Medical Claims And Benefits Payable
MedicalClaimsAndBenefitsPayable
229000000 usd
CY2021Q4 moh Medical Claims And Benefits Payable
MedicalClaimsAndBenefitsPayable
226000000 usd
CY2021Q4 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
3363000000 usd
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
13746000000 usd
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
-311000000 usd
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
13435000000 usd
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
10622000000 usd
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
2411000000 usd
us-gaap Payments For Losses And Loss Adjustment Expense
PaymentsForLossesAndLossAdjustmentExpense
13033000000 usd
moh Liability For Unpaid Claims And Claims Adjustment Expense Business Acquisitions Net Of Post Closing Adjustments
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments
7000000 usd
moh Medical Claims And Benefits Payable Adjustments Change In Provider
MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
3000000 usd
CY2022Q2 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
3775000000 usd
CY2020Q4 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
2696000000 usd
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
11486000000 usd
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
-193000000 usd
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
11293000000 usd
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
9023000000 usd
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
1949000000 usd
us-gaap Payments For Losses And Loss Adjustment Expense
PaymentsForLossesAndLossAdjustmentExpense
10972000000 usd
moh Liability For Unpaid Claims And Claims Adjustment Expense Business Acquisitions Net Of Post Closing Adjustments
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments
-26000000 usd
moh Medical Claims And Benefits Payable Adjustments Change In Provider
MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
-49000000 usd
CY2021Q2 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
2942000000 usd
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
-311000000 usd
CY2022Q2 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
25000000 usd
CY2021Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
27000000 usd
CY2022Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2175000000 usd
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2173000000 usd
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
4 segment
CY2022Q2 us-gaap Revenues
Revenues
8054000000 usd
CY2021Q2 us-gaap Revenues
Revenues
6800000000 usd
us-gaap Revenues
Revenues
15824000000 usd
us-gaap Revenues
Revenues
13322000000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
361000000 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
273000000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
733000000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
608000000 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-27000000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-60000000 usd
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-30000000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-55000000 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
334000000 usd
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
243000000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
678000000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
548000000 usd

Files In Submission

Name View Source Status
R22.htm Edgar Link pending
0001179929-22-000112-index-headers.html Edgar Link pending
0001179929-22-000112-index.html Edgar Link pending
0001179929-22-000112.txt Edgar Link pending
0001179929-22-000112-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
moh-20220630.htm Edgar Link pending
moh-20220630.xsd Edgar Link pending
moh-20220630_cal.xml Edgar Link unprocessable
moh-20220630_def.xml Edgar Link unprocessable
moh-20220630_g1.jpg Edgar Link pending
moh-20220630_htm.xml Edgar Link completed
moh-20220630_lab.xml Edgar Link unprocessable
moh-20220630_pre.xml Edgar Link unprocessable
moh2q22_ex311.htm Edgar Link pending
moh2q22_ex312.htm Edgar Link pending
moh2q22_ex321.htm Edgar Link pending
moh2q22_ex322.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending